association of HAQ change by baseline DAS categories. (DOCX) Author Contributions Formal analysis: Evo Alemao. Methodology: Evo Alemao. Conceptualization: Evo Alemao, Maiwenn J. Al, Maureen P. M. H. Rutten ... . Writing ± original draft: Evo Alemao. Writing ± review & editing: Maiwenn J. Al, Annelies A. Boonen, Matthew D. Stevenson, Suzanne M. M. Verstappen, Kaleb Michaud, Michael E. Weinblatt, Maureen P. M. H
assistance was provided by Stacey Reeber, PhD, at Caudex and was funded by Bristol-Myers Squibb. Disclosures. Harris A. Ahmad is an employee of and has stock options/bond holdings in Bristol-Myers Squibb. Evo ... Alemao is an employee of and has stock options/bond holdings in Bristol-Myers Squibb. Zhenchao Guo is an employee of and has stock options/bond holdings in Bristol-Myers Squibb. Michael Weinblatt has
France; consulting fees: AbbVie, Bristol-Myers Squibb, Celgene, Janssen, Novartis, Pfizer, Roche, UCB; board member: Executive Committee of OMERACT. Souhila Ahdjoudj: employee: Bristol-Myers Squibb. Evo ... Alemao: shareholder and employee: Bristol-Myers Squibb. Vibeke Strand: consulting fees: AbbVie, Alder, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Celltrion, Corrona, Crescendo Bioscience, Genentech
The objective of the study was to examine whether disease duration independently predicts treatment response among biologic-naïve patients with rheumatoid arthritis (RA) initiating abatacept in clinical practice. Using the Corrona RA registry (February 2006–January 2015), biologic-naïve patients with RA initiating abatacept with 12-month (±3 months) follow-up and assessment of...